473 related articles for article (PubMed ID: 31063862)
1. Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study.
Thomas A; Vilimas R; Trindade C; Erwin-Cohen R; Roper N; Xi L; Krishnasamy V; Levy E; Mammen A; Nichols S; Chen Y; Velcheti V; Yin F; Szabo E; Pommier Y; Steinberg SM; Trepel JB; Raffeld M; Young HA; Khan J; Hewitt S; Lee JM
J Thorac Oncol; 2019 Aug; 14(8):1447-1457. PubMed ID: 31063862
[TBL] [Abstract][Full Text] [Related]
2. Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study.
Pakkala S; Higgins K; Chen Z; Sica G; Steuer C; Zhang C; Zhang G; Wang S; Hossain MS; Nazha B; Beardslee T; Khuri FR; Curran W; Lonial S; Waller EK; Ramalingam S; Owonikoko TK
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428583
[TBL] [Abstract][Full Text] [Related]
3. Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.
Lee JM; Cimino-Mathews A; Peer CJ; Zimmer A; Lipkowitz S; Annunziata CM; Cao L; Harrell MI; Swisher EM; Houston N; Botesteanu DA; Taube JM; Thompson E; Ogurtsova A; Xu H; Nguyen J; Ho TW; Figg WD; Kohn EC
J Clin Oncol; 2017 Jul; 35(19):2193-2202. PubMed ID: 28471727
[TBL] [Abstract][Full Text] [Related]
4. CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.
Sen T; Tong P; Stewart CA; Cristea S; Valliani A; Shames DS; Redwood AB; Fan YH; Li L; Glisson BS; Minna JD; Sage J; Gibbons DL; Piwnica-Worms H; Heymach JV; Wang J; Byers LA
Cancer Res; 2017 Jul; 77(14):3870-3884. PubMed ID: 28490518
[TBL] [Abstract][Full Text] [Related]
5. Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer.
Farago AF; Yeap BY; Stanzione M; Hung YP; Heist RS; Marcoux JP; Zhong J; Rangachari D; Barbie DA; Phat S; Myers DT; Morris R; Kem M; Dubash TD; Kennedy EA; Digumarthy SR; Sequist LV; Hata AN; Maheswaran S; Haber DA; Lawrence MS; Shaw AT; Mino-Kenudson M; Dyson NJ; Drapkin BJ
Cancer Discov; 2019 Oct; 9(10):1372-1387. PubMed ID: 31416802
[TBL] [Abstract][Full Text] [Related]
6. Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study.
Krebs MG; Delord JP; Jeffry Evans TR; De Jonge M; Kim SW; Meurer M; Postel-Vinay S; Lee JS; Angell HK; Rocher-Ros V; Meyer K; Ah-See ML; Herbolsheimer P; Lai Z; Nunes A; Domchek SM
Lung Cancer; 2023 Jun; 180():107216. PubMed ID: 37146473
[TBL] [Abstract][Full Text] [Related]
7. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
[TBL] [Abstract][Full Text] [Related]
8. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW;
Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988
[TBL] [Abstract][Full Text] [Related]
9. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
10. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
Ragavan M; Das M
Curr Treat Options Oncol; 2020 Jun; 21(8):64. PubMed ID: 32601742
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.
Zimmer AS; Nichols E; Cimino-Mathews A; Peer C; Cao L; Lee MJ; Kohn EC; Annunziata CM; Lipkowitz S; Trepel JB; Sharma R; Mikkilineni L; Gatti-Mays M; Figg WD; Houston ND; Lee JM
J Immunother Cancer; 2019 Jul; 7(1):197. PubMed ID: 31345267
[TBL] [Abstract][Full Text] [Related]
12. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.
Karzai F; VanderWeele D; Madan RA; Owens H; Cordes LM; Hankin A; Couvillon A; Nichols E; Bilusic M; Beshiri ML; Kelly K; Krishnasamy V; Lee S; Lee MJ; Yuno A; Trepel JB; Merino MJ; Dittamore R; Marté J; Donahue RN; Schlom J; Killian KJ; Meltzer PS; Steinberg SM; Gulley JL; Lee JM; Dahut WL
J Immunother Cancer; 2018 Dec; 6(1):141. PubMed ID: 30514390
[TBL] [Abstract][Full Text] [Related]
13. Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer.
Park S; Kim YJ; Min YJ; Mortimer PGS; Kim HJ; Smith SA; Dean E; Jung HA; Sun JM; Park WY; Ahn JS; Ahn MJ; Lee SH; Park K
Cancer; 2024 Feb; 130(4):541-552. PubMed ID: 37843249
[TBL] [Abstract][Full Text] [Related]
14. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.
Xie M; Vuko M; Rodriguez-Canales J; Zimmermann J; Schick M; O'Brien C; Paz-Ares L; Goldman JW; Garassino MC; Gay CM; Heymach JV; Jiang H; Barrett JC; Stewart RA; Lai Z; Byers LA; Rudin CM; Shrestha Y
Mol Cancer; 2024 May; 23(1):115. PubMed ID: 38811992
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy.
Choy E; Butrynski JE; Harmon DC; Morgan JA; George S; Wagner AJ; D'Adamo D; Cote GM; Flamand Y; Benes CH; Haber DA; Baselga JM; Demetri GD
BMC Cancer; 2014 Nov; 14():813. PubMed ID: 25374341
[TBL] [Abstract][Full Text] [Related]
16. Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.
Senan S; Okamoto I; Lee GW; Chen Y; Niho S; Mak G; Yao W; Shire N; Jiang H; Cho BC
Clin Lung Cancer; 2020 Mar; 21(2):e84-e88. PubMed ID: 31948903
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.
Kim YJ; Keam B; Ock CY; Song S; Kim M; Kim SH; Kim KH; Kim JS; Kim TM; Kim DW; Lee JS; Heo DS
Lung Cancer; 2019 Oct; 136():122-128. PubMed ID: 31494530
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of olaparib combined with pembrolizumab in second-line treatment for extensive-stage small cell lung cancer].
Wu ZZ; Zhang SJ; Hu Y
Zhonghua Zhong Liu Za Zhi; 2020 Jul; 42(7):590-593. PubMed ID: 32842449
[No Abstract] [Full Text] [Related]
19. A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
Chia S; Bedard PL; Hilton J; Amir E; Gelmon K; Goodwin R; Villa D; Cabanero M; Tu D; Tsao M; Seymour L
Oncologist; 2019 Nov; 24(11):1439-1445. PubMed ID: 31420468
[TBL] [Abstract][Full Text] [Related]
20. Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer.
Owonikoko TK; Zhang G; Kim HS; Stinson RM; Bechara R; Zhang C; Chen Z; Saba NF; Pakkala S; Pillai R; Deng X; Sun SY; Rossi MR; Sica GL; Ramalingam SS; Khuri FR
J Transl Med; 2016 May; 14(1):111. PubMed ID: 27142472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
